Sclerotherapy
PreclinicalSmall molecule
Sclerotherapy is one of 28 small molecule programs targeting Granuloma. It is currently in Preclinical.
2
Indications
4
Total Trials
2
Active Trials
27
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
27 competitors in Hemorrhoid
#DrugCompanyPhaseTrials
1Isordil
AstraZenecaApproved
Botox
RRevance Therapeutics, Inc.
Approved
Ketalar
AAultman Health Foundation
Approved
Marcaine
IInnocoll
Approved
Cardizem
BBausch Health Americas, Inc.
Approved
Nitrostat
VViatris Specialty LLC
Approved
Kenalog
BBassett Healthcare
Approved
Neo-Synephrine
EExela Pharma Sciences, LLC.
Approved
Celestone
SSchering-Plough
Approved
Decadron
AAspen Global Incorporated
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Hereditary Hemorrhagic Telangiectasia1 trial
Hemorrhoid1 trial
Granuloma1 trial
Effect of Laser and Sclerotic Agent in the Treatment of Oral Granuloma
Not yet recruiting·—·N/A·NCT06639230·20 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Sclerotherapy. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- UUniversity of Minnesota